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Abstract
Background: Post-transplant lymphoproliferative disorder (PTLD) is a spectrum of hematological
diseases arising in context of immunosuppression after organ transplantation. PTLD can involve any
organ; however, it is extremely rare in oral cavity.
Methods: Using morphologic and immunophenotypic approaches we have studied a case of
monomorphic PTLD of the tongue that developed in a patient following unilateral kidney and
pancreas transplantation on immunosuppressive therapy. Additionally, cases of PTLD in the oral
cavity were reviewed in the English literature.
Results: The neoplasm showed large cell morphology and B-cell phenotype. In situ hybridization
for Epstein-Barr virus was positive. Complete remission was obtained after decreasing
immunosuppressive therapy. The patient remained in remission at 790 days' follow up.
Conclusion: This rare case increased our awareness of PTLD in the oral cavity of patients
following solid organ transplantation and immunosuppressive therapy.
Introduction
Post-transplant lymphoproliferative disorder (PTLD) is a
well-recognized complication after solid organ or bone
marrow transplantation. It comprises a spectrum of path-
ologic patterns ranging from reactive Epstein-Barr virus
(EBV)-driven lymphocytic/plasmacytic hyperplasia to
high-grade malignant lymphomas [1]. PTLD may involve
the lymph nodes or extranodal tissue at any site, including
the organ allograft [2]. A series of 90 PTLD cases occurring
in 4283 solid organ transplantations over a nine-year
period revealed that two thirds of the patients presented
with disease in a single site [3], and none of the cases pre-
sented in the tongue at diagnosis. Here we report a rare
case of monomorphic PTLD of the tongue in a patient
after kidney and pancreas transplantation, which was
effectively treated solely by reduction of immunosuppres-
sion. Review of the English literature reveals only a few
such cases that involve oral cavity (Table 1).
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Table 1: Literature review of Posttransplant lymphoproliferative disorders (PTLD) arsing in the oral cavity
Author Age & sex, site Onset Diagnosis, site EBV status Treatment Follow up
Doak et al 1968 34 , kidney 180 days Reticular Cell Sarcoma, tongue & oral cavity Viral inclusions Antimycotic Medication NOS Died 30 days after
Staddlemann et al 1996 65 , kidney 600 days NK/T-cell lymphoma, pharynx Positive Cyclosporine d/c, Four cycles CHOP Remission for 1080 days
Reams et al 2003 16 , R + L lung 330 days Polymorphic B-cell lymphoma, tongue Negative Four cycles of Rituximab Patient died of Sepsis
Rolland et al 2004 60 , heart 3600 days Peripheral T-cell lymphoma NOS, gingiva Positive Azathioprine d/c, decrease Cyclosporin Remission for 360 days
Rolland et al 2004 61 , heart 1410 days DLBCL, maxilla Posotive Stepwise decrease in Ciclosporin Recurrences at 180 and 510 days
Bruce et al 2006 45 , pancreas 660 days DLBCL, tongue Positive Sirolimus d/c Tacrolimus adjusted Remission 660 days, AR
Gonzalez-Cuyar et al 2007 47, , kidney pancreas 720 days DLBCL, tongue Positive Decreased immunosupression Remission for 790 daysDiagnostic Pathology 2007, 2:49 http://www.diagnosticpathology.org/content/2/1/49
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Case presentation
A 47-year-old Caucasian male with history of Diabetes
Mellitus type I underwent simultaneous pancreas-kidney
transplantation two years prior to the current admission.
Past medical history also included depression and 20
pack-year smoking with cessation 10 years ago. At admis-
sion he presented with sore throat, progressive dysphagia,
odynophagia, and weight loss. His immunosuppression
regimen included tacrolimus (8 mg/day) and prednisone
(5 mg/day). The physical exam was remarkable for a 4 cm
exophytic lesion at the right base of tongue that appeared
to extend to the inferior pole of the tonsillar fossa, as well
as marked right cervical lymphadenopathy. Computed
tomographic (CT) scan of the neck revealed an ill-defined
mass in the right peripharyngeal region at the base of the
tongue with deviation of the airway to the left (Figure 1A).
In addition, a conglomerate mass representing a group of
involved lymph nodes invading the right sternocleido-
mastoid muscle was also identified (Figure 1B). CT scan of
the abdomen showed enlarged right mesenteric lymph
nodes and an area of thickening of the small bowel wall.
A panendoscopy with biopsy of the right base of the
tongue lesion was performed. The hematoxylin-eosin
(H&E) stained sections showed sheets of monotonous
large atypical lymphoid cells with abundant cytoplasm,
large vesicular nuclei and occasional prominent nucleoli
(Figure 2A). These neoplastic cells infiltrated the adjacent
skeletal muscles of the pharynx. Mitotic figures were rare.
Large foci of necrosis were noted. Immunohistochemical
stains demonstrated that the large cells were positive for
CD20 (Figure 2B), CD30, BCL2, CD38 and EBV latent
membrane protein (LMP) (Figure 2C). CD5 was aber-
rantly expressed in these cells. These cells were negative
for CD3 and CD79a. Staining for immunoglobulin light
chains kappa and lambda revealed only a few scattered
polyclonal plasma cells. Molecular studies revealed IGH
gene rearrangement in the neoplastic cells. Given the
patient's history of solid organ transplantation and
immunosuppression, it was diagnosed as monomorphic
PTLD, consistent with diffuse large B-cell lymphoma. A
CT scan of the pancreas and kidneys was negative for
tumor. Repeated bone marrow biopsies were also negative
for lymphoma involvement.
The immunosuppressive agents were withdrawn and the
patient was closely followed. Ten weeks after the cessation
of immunosuppressive therapy, the oral lesion had com-
pletely regressed and repeated CT scans of the head, neck
and abdomen were constantly negative. Subsequent biop-
sies of the oral cavity were also negative. The patient has
been followed for over 790 days and he currently remains
in remission on lower doses of immunosuppressants, and
with functioning allografts.
Discussion
We have presented a rare case of monomorphic PTLD of
the tongue with a complete remission after withdrawal of
immunosupression. Through this case, we have also illus-
trated another successful example of managing the immu-
nodeficiency-associated malignant lymphomas.
Images of computed tomography (CT) without contrast Figure 1
Images of computed tomography (CT) without contrast. A. 
Lesion at the base of tongue (indicated by an arrow); B. Con-
glomerate mass invading the right sternocleidomastoid mus-
cle (indicated by an arrow).Diagnostic Pathology 2007, 2:49 http://www.diagnosticpathology.org/content/2/1/49
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Recognition of PTLD as a clinical entity can be traced back
to the mid 20th century when the association between host
immune response and immunosuppressive therapy with
neoplasia was suggested, specially after solid organ trans-
plantation [4-6] However, the development of hemato-
logical malignancies following transplantation of solid
organs attributed to immunosuppressive therapy was first
described by Doak et al [7] in 1968. In this report Doak
and colleagues presented a 34 year-old man with history
of renal transplantation who was treated with azathio-
prine and prednisone. Six months after the transplant, the
patient presented with oral ulcers, which grew Candida
species, and were initially treated with antimycotic medi-
cation. He died a month thereafter. Autopsy revealed mul-
tiple oral cavity, tongue, esophageal, and hepatic lesions
that were composed of polygonal lymphoid cells with
scant pale cytoplasm and large hyperchromatic nuclei.
These were associated with occasional foci of necrosis,
multinucleation, viral inclusions, macronucleoli and
mitoses. At the time, it was referred to as reticular cell sar-
coma.
In 1969 Penn et al [5] reported a case of a renal transplant
patient on azathioprine and prednisone who developed a
rapidly progressive left hemiparesis. Brain biopsy revealed
a tumor of lymphoid origin. The patient was given radio-
therapy with synchronous dosage reduction of the immu-
nosuppressive therapy. He demonstrated marked
neurologic improvement with shrinkage of the mass. Two
decades later Starlz et al [8] first used the term post-trans-
plant lymphoproliferative disorder (PTLD) and suggested
that reduction and/or discontinuation of immunosupres-
sive medications could lead to regression of the post-
transplant malignancies.
Stadlmann et al [9] presented a 65-year-old male patient
who had undergone kidney transplant in March of 1996.
Twenty months later, he developed a small ulcer on the
posterior aspect of the pharynx. The patient was serologi-
cally positive for EBV, and was on cyclosporine, pred-
nisolone and azathriopine. Biopsy of the ulcer was
diagnosed as a posttransplant associated NK/T cell lym-
phoma. Cyclosporine was subsequently discontinued and
4 cycles of chemotherapy with CHOP (cyclophospha-
mide, doxorubicin, vincristine and prednisone) were
given. A three years' follow up revealed that the patient
was still in remission.
In 2003, Reams et al published a series of 400 recipients
of lung and/or heart transplant; among them 10 patients
developed PTLD. Of particular interest was a 16-year-old
female patient who had a history of cystic fibrosis status
post bilateral lung transplantation and who was negative
for EBV. Her immunosuppressive regimen consisted of
cyclosporine A, azathioprine and metylprednisolone.
Microphotographs of the monomorphic PTLD Figure 2
Microphotographs of the monomorphic PTLD. A. Large lym-
phoid cells with abundant cytoplasm, vesicular nuclei and 
prominent nucleoli (H&E, 400× magnification); B. Neoplastic 
cells positive for CD20 (immunoperoxidase stain, 400× mag-
nification); C. Neoplastic cells positive for EBV LMP (immu-
noperoxidase stain, 400× magnification).Diagnostic Pathology 2007, 2:49 http://www.diagnosticpathology.org/content/2/1/49
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Three-hundred and thirty days after the transplant the
patient developed a lesion in the left base of tongue. She
was diagnosed to have a polymorphic B-cell PTLD. After 4
cycles of rituximab, the patient died of sepsis.
In 2004 Rolland et al [10] reported two cases of oral PTLD
in two patients with heart transplantation. The first
patient was a 60-year-old male who was immunosu-
pressed with azathriopine, cyclosporin, and prednisolone.
During the first ten years following transplantation he had
multiple episodes of gingival swelling that were attributed
to cyclosporin. Biopsy of the gingiva demonstrated EBV-
driven peripheral T-cell lymphoma, NOS. Azathrioprine
was discontinued and cyclosporin was decreased. The
patient was in remission for one year after the immunosu-
pression adjustment. The second patient was a 61-year-
old man who was on azathriopine, cyclosporin and pred-
nisolone, and developed swelling of the maxilla and gin-
giva. Biopsy showed an EBV-driven diffuse large B-cell
lymphoma with focal plasmablastic differentiation. The
immunosuppressive therapy was adjusted and subse-
quently had two recurrences at 6 and 17 months post
transplantation, which were treated effectively by stepwise
decrease of cyclosporin.
Bruce et al [11] in 2006 presented a case of a 45-year-old
female patient who was status post pancreatic transplan-
tation and on an immunosuppressive regimen consisting
of sirolimus, tacrolimus, and prednisone for 22 months.
She presented with an ulcer on the ventral aspect of the
tongue. Differential diagnosis of the lesion included gran-
uloma of the tongue, infection and drug induced ulcera-
tion. Sirolimus was discontinued, tacrolimus was
adjusted and a superficial biopsy was obtained. The
biopsy revealed a traumatic granuloma with rare EBV+
lymphocytes by in-situ hybridization (EBER). Subse-
quently the entire lesion was resected and diagnosed as
monomorphic EBV-associated PTLD, diffuse large B-cell
lymphoma. The patient was followed for two years and
was still in remission, but developed chronic rejection of
the allograft.
Transplant recipients have a five-fold increased risk of
developing  de novo head and neck malignancies when
compared to general population [12,13], of which the
most common neoplasms are skin cancers [13,14] In the
transplant population the incidence of PTLD is approxi-
mately 2%[11,15]. PTLD is a spectrum of lymphoprolifer-
ative disorders in patients who have undergone solid
organ or bone marrow transplantation in the setting of
immunosuppression [16], with EBV implicated in 2–5 %
of adult patients [3] and of up to 20% of pediatric patients
[16]. In the latter population it has been suggested that
EBV-associated adenotonsilar enlargement could be a pre-
cursor to PTLD [17]. On average, patients have been diag-
nosed 2 years after transplantation [13]. In these patients,
immunosuppression decreases the immunosurveillance
of EBV-specific T-cells; and thus allows subsequent prolif-
eration of EBV-infected B-cells [18-20]. Early develop-
ment of PTLD is often associated with EBV infection and
thus responds to reduction in immunosupression. How-
ever, later onset PTLD does not respond to reduced immu-
nosuppression [20]. Later onset EBV-negative PTLD has
also been reported and generally has a more aggressive
clinical course [18-20].
The organs involved by PTLD vary depending on the dif-
ference in immunosuppressive regimens. The allograft
itself is involved in only 25% of the cases [19]. Patients
treated with tacrolimus often develop nodal and gastroin-
testinal PTLD [2,18]. In our patient, PTLD developed in
the tongue as well as the possible lymph node (cervical
and mesenteric) and gastrointestinal tract (as demon-
strated by CT scan). Although the oral cavity may be
regarded as the uppermost part of the gastrointestinal
tract, reports of PTLD involvement of the tongue are
extremely rare.
Initial treatment for PTLD is to reduce immunosupression
[1]. A response is usually seen within 2–4 weeks of with-
drawal of immunosupression [21], and reduction in
immunosupression alone leads to long-term disease-free
remission in 25–73% of adults [15,22]. The chances of
complete remission seem to be directly related to the
degree of differentiation of the neoplasm. Early and infec-
tious mononucleosis-like lesions tend to regress more
often with reduction in immunosupression alone, com-
pared to monomorphic PTLD. A proportion of cases of
both types, however, requires chemotherapy [23]. The
benefit of withdrawing immunosupression and the risk of
transplant rejection need to be carefully reconciled. The
institution of chemotherapy also brings inherent risks of
infections and de novo malignancies. Antiviral agents seem
to have some effects on the early hyperplasic lesions
[24,25]. However, these agents do not have significant
effects on the lesion once monoclonality has emerged
[26].
Although lymphoid malignancies of the tongue and oral
cavity have previously been reported [27-30], complete
remission of diffuse large B-cell lymphoma after with-
drawal of immunosupression has rarely been docu-
mented, particularly in cases of PTLD. A consensus in the
treatment of PTLD with maximum safety to the organ
allograft is yet to be attained. However, the current report
demonstrates the efficacy of reduction of immunosupres-
sion in the management of some cases of EBV-driven
PTLD, even in the form of a high-grade diffuse large B-cell
lymphoma.Diagnostic Pathology 2007, 2:49 http://www.diagnosticpathology.org/content/2/1/49
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Another common dilemma is differentiation opportunis-
tic infections and PTLD. Patients with immunosupression
after organ transplantation are at increased risk of infec-
tions and sepsis [31]. However, it should be noted that
opportunistic infections with positive tissue and/or blood
cultures might mask an underlying hematological malig-
nancy [4,6,7,23]. Since immunosupressed patient are at
increased risk of developing opportunistic infections and
hematological malignancies, both possibilities need to be
considered on the differential diagnosis. This case report
stresses the importance of obtaining biopsies of oral cav-
ity lesions in immunosuppressed patients following solid
organ transplantation to direct appropriate treatment in a
expeditious fashion.
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